ArticleThe oncologist2016
A Case of Nivolumab-Induced Myositis.
Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase.Frontiers in immunology · 2025Article
- Immunotherapy-Induced Eosinophilic Tracheitis.Cureus · 2022Article
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.Journal for immunotherapy of cancer · 2021Article
- Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.Cancer science · 2021Article
- Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?The oncologist · 2020Article
- Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.Rheumatology (Oxford, England) · 2019Review
- Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.Thoracic cancer · 2019Article
- Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.Current rheumatology reports · 2019Review
- Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.Current neurology and neuroscience reports · 2018Review
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.Current neurology and neuroscience reports · 2018Review
- Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.Current drug safety · 2018Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.